Although the incidence of anemia in patients with inflammatory bowel disease (IBD), which comprises ulcerative colitis and Crohn’s disease, has reportedly decreased in the last few decades, it is still the most prevalent extraintestinal complication of IBD. Continue reading “Evaluating Anemia Care Pathways to Assess and Manage Iron-Deficiency and Anemia in Patients with IBD”
Assessing the Impact of Anemia in Patients with IBD
Although the incidence of anemia in patients with inflammatory bowel disease (IBD), which comprises ulcerative colitis and Crohn’s disease, has reportedly decreased in the last few decades, it is still the most prevalent extraintestinal complication of IBD. Continue reading “Assessing the Impact of Anemia in Patients with IBD”
The Value of Biosimilars in the Treatment of IBD: Frequently Asked Questions
Biosimilars offer additional treatment options for patients with IBD. In this activity, faculty will review the role of biosimilars in the management of IBD and answer learner questions from the previous CME activity. Continue reading “The Value of Biosimilars in the Treatment of IBD: Frequently Asked Questions”
The Value of Biosimilars in Inflammatory Bowel Disease
A number of biosimilars have been approved in recent years, offering additional treatment options for patients with IBD. Given the novelty of biosimilars in the U.S., it’s not surprising that clinicians have questions. Continue reading “The Value of Biosimilars in Inflammatory Bowel Disease”